The estrogen receptor (ER) and progesterone receptor (PR) are over-expressed in ~50% of breast cancer lesions, and used as biomarkers to stratify patients to endocrine therapy. Currently, 
INTRODUCTION
Steroid hormone receptors (SHR) regulate cellular function in healthy tissue, however, over-activation of some SHRs promote the proliferation of hormone-responsive cancer.
1 A definitive example, endogenous estrogen binding to the estrogen receptor (ER), triggers tumor proliferation in 70 -80%
of cases of breast cancer and 33 -53 % of ovarian cancers. [2] [3] Progesterone receptor (PR) expression is regulated by the ER and can consequently behave as a surrogate biomarker to report on ER function. As a result, ER and PR expression have predictive and prognostic importance, allowing patients to be stratified into responders/non-responders of endocrine therapy, the frontline treatment for ER+ tumors. 4 The current gold standard for assessment of ER/PR expression is ex vivo immunohistochemistry (IHC) which is prone to misrepresent heterogeneity of receptor expression. [5] [6] [7] Positron emission tomography (PET) may overcome the limitations of IHC by quantifying receptor expression in metastatic lesions where biopsy sampling is challenging, while also accounting for heterogeneous receptor expression in primary disease. The use of the ER-targeted radioligand, 16α- involving primary and metastatic breast cancer. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] Further integration of [
F]FES-PET into routine
clinical experience is hampered by rapid metabolism and the difficulty of imaging patients receiving endocrine therapy owing to competition for ER between the radioligand and the therapeutic agent. 19 This has prompted investigation into PR targeted radioligands to report on the presence of a functional ]FFNP could report on response to endocrine therapy. [20] [21] [22] Although studies into [
18 F]FFNP as a radioligand for imaging PR expression have been promising, its physicochemical properties, e.g., high
LogP associated with the steroidal structure of the ligand may compromise specificity for PR binding.
Tanaproget ( Figure 1 ) is a high affinity, highly specific, non-steroidal PR agonist (EC50 = 0.15 nM)
developed by Wyeth as an orally bioavailable contraceptive. 23 Tanaproget derivatives have previously been investigated for use as radioligands where derivatization at the R2-position provided racemic Figure 1A . [24] [25] [26] [27] The relative binding affinities (RBA) of Tanaproget and related   18 F-labelled scaffolds are shown in Figure 1B . were synthesized and evaluated for PR binding affinity (data summarized in Figure 1B ). 24 The affinity data reported by Zhou and co-workers indicates an inverse relationship between fluoroalkyl chain length and PR binding affinity. Based on this observed trend we reasoned that N-fluoromethylalkylation could provide a radioligand with improved PR binding affinity. 25 Herein we describe the synthesis and evaluation of a Tanaproget derivative that features facile access to a radiolabeling precursor and a simple radiolabeling strategy.
RESULTS AND DISCUSSION
Synthesis of the reference compound (6). The reference compound 6 was tested for PR potency to verify our hypothesis concerning probe design (prior to any radiolabeling); chemical methodology is °C were all studied, but gave minimal radiochemical incorporation (<1% by analytical HPLC), whilst the reaction did not proceed as cleanly without the presence of K2CO3 as a base, with up to two other radiochemical peaks noted in the absence of K2CO3. The product was isolated using semi-preparative HPLC and reformulated into ethanol, before being diluted down using saline solution to less than 5% ethanol content in the formulated mixture. Specific activity was routinely found to be between 10 and 20 GBq. Radiochemical stability of > 99% was found upto 4 hours in ethanol and saline independently. Progesterone (filled triangles) and compound 6 (filled squares) were tested.
Binding specificity. Compound 6 was studied for cross-reactivity to other steroid receptors including GR, AR and ER using luciferase reporter assays ( Figure 3 ). Dexamethasone, a GR ligand exhibited high luciferase activity in keeping with activation of GR reporter; MPA (medroxyprogesterone acetate), a potent progesterone agonist, had minimal GR activity while compound 6 showed negligible activation of GR ( Figure 3 ). DHT interacted with AR with ~10-15-fold activation at concentrations up to 1 µM. MPA and compound 6 increased AR activation by ~2.5-fold at 1 µM. In the ER luciferase reporter assay, compound 6 and MPA activated the receptor by approximately 2-fold less than estrogen (Figure 4) . These assays demonstrated high specificity of compound 6 for PR (low nonspecific interaction with related receptors). light units using firefly luciferase; in the case of A, the RLU of firefly luciferase to that of renilla luciferase was determined (thus, RLU ratio).
In vitro cell uptake study. Subsequently, in vitro uptake experiments were carried out using [ Most steroid-based PR ligands exhibit sub-nanomolar affinity and it may be the case that, similarly high affinity is required for non-steroidal imaging ligands. An avenue of interest for further research is the development of higher affinity PR ligands, which could potentially be achieved using a medicinal chemistry based fragment screening campaign. The specific activity of [ 18 F]6 was estimated to be about 10 GBq/mol. In a mouse weighing 20g this would equate to a dose of cold Tanaproget served as a useful starting point for developing PR imaging agents investigated herein and previously, however, we have shown that even with careful consideration when derivatizing the structure, deviation from sub-nanomolar affinity and poor metabolic stability can hinder the development of an effective in vivo imaging agent. Attracted by the sub-nanomolar affinity of tanaproget, we decided to investigate carbon-11 radiolabeled Tanaproget, accessed via a novel minutes before being cooled and diluted with 8 mL of 2:3 H2O:MeCN and injected on semipreparative HPLC (Phenomenex Luna C18, 250 × 10, 2:3 H2O:MeCN, 3 mL/min). The labelled product 6 was collected (Rt = 9 min) and subsequently reformulated using tC18 light SPE cartridge (prepared with 2 mL EtOH and 5 mL H2O) after being diluted with 10 mL of H2O. 
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